News

The director of the CCU/ICU at Saint John’s Health Center discussed updated data from a phase 1/2 trial of agenT-797.

Seelos Therapeutics’ SLS-004 showed the ability to downregulate α-synuclein, and CENTOGENE’s ROPAD study will be extended.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

Several phase 3 trials for AlloVir’s posoleucel are expected to complete enrollment in 2023.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer, CLL Society, discussed the role the society plays in the field.

Review top news and interview highlights from the week ending January 13, 2023.

The chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.

Tenaya Therapeutics expects the dosing of the first patient in the planned phase 1b trial in Q3 2023.

The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of B4t2-001.

Athersys has made progress in enrollment with its MATRICS-1 and MASTERS-2 clinical trials.

The FDA made the decision in response to manufacturing process information that it considered a major amendment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.

Instil Bio, ITIL-306’s developer, expects to present initial data from the phase 1 trial’s dose escalation cohorts this year.

The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.

Some patients previously treated with GNT-003 were able to maintain the stoppage of phototherapy for at least 1 year.

huMNC2-CAR22 is designed to avoid off-tissue expression and reduce T-cell exhaustion.

The new analysis data was requested by the FDA ahead of the therapy’s March 31, 2023 PDUFA date.

No serious adverse events related to the gene therapy have been reported.

Phase 1/2 studies evaluated PDA001 in 50 participants with CD.

The company expects to provide initial data from the trial in the second half of this year.

Brent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.

CKO804 is being evaluated as an add-on therapy to ruxolitinib in patients whose disease had a suboptimal response to ruxolitinib alone.

Promising results were previously reported from a proof-of-concept study involving 8 patients.

The first patient dosed in the study experienced a case of prolonged pancytopenia that has required ongoing transfusion and growth factor support.

Review top news and interview highlights from the week ending January 6, 2023.

The company is kicking off 2023 by announcing planned advancements for several gene therapies in its pipeline.

Initial data from the trials of HMI-103 and HMI-203 are expected in 2023.